arrow
R

Rebecca Deyell

bc children's hospital
H指数:20
被引数:1,394

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Patient-reported Genetic testing Utility InDEx: A novel measure of personal utility

患者报告的遗传检测效用指数:一种新型个人效用衡量方法

2026-09-010
PRE
Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study

bortezomib和vorinostat联合米托蒽醌、地塞米松和聚乙二醇化门冬酰胺酶在诱导和再诱导期间用于婴儿急性淋巴细胞白血病的治疗方案:一项多中心单臂Ⅰ/Ⅱ期研究

2026-02-120
OAAI
A Real-World Analysis of Outcomes in CIC-Rearranged Sarcomas: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) Study

CIC易位型肉瘤真实世界结局分析:加拿大肉瘤研究与临床合作(CanSaRCC)研究

2026-01-190
OAAI
Improved Outcomes for Older Children, Adolescents, and Young Adults With Neuroblastoma in the Post-Immunotherapy Era: An Updated Report From the International Neuroblastoma Risk Group

Deyell, R.J.; Srivatsa, K.; Angelini, P.; Kao, P.C.; Payne, B.; Naranjo, A.; Castelli, S.; Kato, M.; Ohira, M.; Poetschger, U.; 等. 免疫疗法时代后,神经母细胞瘤患儿的预后改善:国际神经母细胞瘤风险组更新报告. Pediatr. Blood Cancer 2026, 73, e70124. [Google Scholar] [CrossRef]

2026-01-012
OAAI
mTOR Inhibition in the Management of Recurrent Metastatic Solid Pseudopapillary Tumor of the Pancreas

mTOR抑制剂在复发性转移性胰腺实性假乳头状瘤管理中的应用

2025-12-010
PRE
Proteomics and personalized PDX models identify treatment for a progressive malignancy within an actionable timeframe

蛋白质组学和个性化PDX模型识别出在可操作时间框架内针对进展性恶性肿瘤的治疗方案

2025-04-010
OA
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN UPDATED ANALYSIS
2024-11-110
PRE
Transcriptome-based assessment of immune infiltration for molecular selection of pediatric patients with solid tumors for combination immune checkpoint inhibitor therapy
2024-09-050
PRE
Whole genome and transcriptome integrated analyses guide clinical care of pediatric poor prognosis cancers
2024-05-163
OAAI
Prioritizing treatment targets for an adolescent with metastatic processive malignancy using proteomics and personalized xenograft models within an actionable timeframe
2024-03-220
PRE
Performance of the eHealth decision support tool, MIPOGG, for recognising children with Li-Fraumeni, DICER1, Constitutional mismatch repair deficiency and Gorlin syndromes
2023-07-174
PRE
Parents' expectations, preferences, and recall of germline findings in a childhood cancer precision medicine trial
CANCER
IF5.1
2023-06-297
OAAI
Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
2023-05-0122
OAAI
A pan-Canadian precision oncology program for children, adolescents and young adults with hard-to-cure cancer: The PRecision Oncology For Young peopLE (PROFYLE) Program
2023-04-042
PRE